Clinical and methodological considerations on the results of the SENSCIS trial: Comment on the article by Maher et al.

AbstractI read with interest the reanalysis of the results of the SENSCIS trial, published by Maher et al (1). The article may represent an advance in the knowledge of the effects of nintedanib in systemic sclerosis-associated interstitial lung disease (SSc-ILD), but there are aspects that deserve additional comments.
Source: Arthritis and Rheumatology - Category: Rheumatology Authors: Tags: LETTER TO THE EDITOR Source Type: research